All News

LBP,back,man,spine

Low Back Pain? Take a Walk!

d Jack Cush, MD

A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.

Read Article
kidney-147499_640.png

Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis

d Jack Cush, MD

A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use.

Read Article
mtx.png (keep)

No Risk of Interstitial Lung Disease with Methotrexate Use

d Jack Cush, MD

JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).

Read Article
JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/hMmrifhiNN https://t.co/LPHc5GyOaA

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria https://t.co/fBtoTQy5Wx https://t.co/rbvaqy0oyC

Links:

Dr. John Cush RheumNow ( View Tweet)
Artificial Intelligence: Detection of CPPD on Hand Radiographs Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria. https://t.co/jQrwKXuaDc https://t.co/Ecv69wvHxA

Links:

Dr. John Cush RheumNow ( View Tweet)
In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/bVYjnBqpaf

Links:

Dr. John Cush RheumNow ( View Tweet)

Abatacept Misses on Shingrix Response Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria. https://t.co/3Tp777HVTD https://t.co/PRrjm65nFK

Links:

Dr. John Cush RheumNow ( View Tweet)
"AMPLIFIED study: abatacept vs adalimumab in RF+ACPA+ early RA Not a single blink of difference. Maybe for high CCP titre but the inverse for low CCP. Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007

Dr. John Cush RheumNow ( View Tweet)

EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/oW6NBjIG7E https://t.co/toyvHxJlr9

Links:

Dr. John Cush RheumNow ( View Tweet)
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (& good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020

Dr. John Cush RheumNow ( View Tweet)

EULAR 2024 Rheumatology Roundup Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna https://t.co/TqEAuk0PGp https://t.co/erRZ3cLxhu

Links:

Dr. John Cush RheumNow ( View Tweet)
SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085

Dr. John Cush RheumNow ( View Tweet)

PsA: Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. https://t.co/xA8YYCi94r https://t.co/RyS6vnlzam

Links:

Dr. John Cush RheumNow ( View Tweet)
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/NUZ3cc4bUx https://t.co/nGP10y3Kuw

Links:

Dr. John Cush RheumNow ( View Tweet)
BiTEs (Bispecific T cell engagers) kill B cells by engaging T cells. IV blinatumomab (CD19xCD3 BiTE) rx of 6 refractory RA pts, led to B & T cell depletion, rapid decline Dz activity, synovitis, autoAbs & was safe, w/ brief temp & ^CrP w/ 1st rx https://t.co/ebLsknirtQ https://t.co/eEIch4g0I1

Links:

Dr. John Cush RheumNow ( View Tweet)
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Tapering Treatment for Lupus Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus. https://t.co/ijy5OwIoCe https://t.co/7yQIxW70Zd

Links:

Dr. John Cush RheumNow ( View Tweet)
Cognitive Function in Older Adults: Worse in Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk

Links:

Dr. John Cush RheumNow ( View Tweet)
×